With the majority of voters on both sides of the aisle saying Congress’s top priority should be lowering high drug costs, an upcoming U.S. Supreme Court case could significantly hamper the country’s ability to lower the price of medicine and assess and remove unmerited pharmaceutical patents. This policy brief examines the little-discussed health implications of Oil Energy States v. Greene’s Energy Group, which will address the constitutionality of the U.S. Patent and Trademark Office’s process to help make sure patents meet legal requirements.